['type 2 diabetes']
['saxagliptin', 'dapagliflozin', 'sitagliptin', 'placebo matching with saxagliptin', 'placebo matching with dapagliflozin', 'placebo matching with sitagliptin']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control,
             defined as a central laboratory glycosylated hemoglobin (HbA1c) ≥8.0% and ≤ 10.5 %
             obtained at the screening visit

          -  Subjects should have been taking the same daily dose of metformin ≥ 1500 mg for at
             least 8 weeks prior to the enrollment visit and with no intake of other
             antihyperglycemic therapy for more than 14 days (consecutive or not) during 12 weeks
             prior to screening

          -  BMI > 20.0 kg/m2 at the enrollment visit

          -  Males and Females, age ≥18 years old at time of screening visit

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug

          -  Women must not be breastfeeding

        Exclusion Criteria:

          -  Clinically diagnosed with Type I diabetes, known diagnosis of Maturity Onset Diabetes
             of Young (MODY), secondary diabetes mellitus or diabetes insipidus

          -  History of diabetic ketoacidosis

          -  Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the
             enrollment visit

               -  Myocardial infarction

               -  Cardiac surgery or revascularization (coronary artery bypass surgery Coronary
                  Artery Bypass Graft [(CABG)]/percutaneous transluminal coronary angioplasty
                  percutaneous transluminal coronary angioplasty [(PTCA)])

               -  Unstable angina

               -  Unstable congestive heart failure (CHF)

               -  Transient ischemic attack (TIA) or significant cerebrovascular disease

               -  Unstable or previously undiagnosed arrhythmia

               -  Congestive heart failure, defined as New York Heart Association (NYHA) Class III
                  and IV, unstable or acute congestive heart failure and/or known left ventricular
                  ejection fraction of ≤ 40%

          -  Renal Disease

          -  Hepatic Diseases

          -  Hematological and Oncological Disease/Conditions

          -  Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women

          -  Abnormal Free T4
      